sale y/i significantli exceed our/street
led out-performance patient access initi led
pharmaci channel transit strong driver new patient start us
intern strength continu broad-bas canada new
driver manag rais sale guidanc impli y/
growth non-gaap oper margin rais
competit remain high overal market acceler continu
numer driver ahead includ continu pharmaci channel expans pump
partner launch recent launch medicar patient intern expans
japan particular focu on-track limit launch
see potenti share gainer market expand
us/ou sale exceed forecast
commerci busi primari us driver medicar solid
expect acceler launch intern manag
highlight launch canada acceler uk perform standout
revenue-per-pati headwind expect access initi payer
initi strong perform led effort payer
broader access reduc up-front administrative/cost burden
guidanc builds-in revenue-per-pati headwind payer
discuss new patient growth initi offset
manag note capac doubl exit year capac
expect doubl
pipelin final step design lock-down underway build
autom product line limited-launch on-track
broader launch low-cost extend wear dispos design
provid benefit current focused-on market open big new
market start non-intens geograph expans continu
guidanc sale earn guidanc rais
beat despit challeng one product line led
temporari lower product capac sinc resolv sale gm guidanc
vs previous take account guidanc upsid potenti
base on-going capac expans initi
estim sale estim increas
us/ou ep rise higher sale
oper leverag forecast sale
ep ou expans potenti upsid driver
higher estim pt rise
year price histori
medic devic
compani focus design
develop continu glucos
monitor system diabet patient
lead product cgm
analyst certif import disclosur see disclosur
under-penetrated patient popul robust pipelin
forecast strong sale growth next sever year
competit remain high particularli libr
launch new market
cgm penetr type diabet reach long-term
us growth remain solid market channel
expans well medicar contribut off-set lower revenue-p
modest acceler intens type patient non-medicar
greater volum acceler pharmaci access
type contribut sale beyond current modest current
launch hybrid closed-loop system pump partner
competitor launch lead greater market share loss
price target driven blend discount cash flow assum weight averag cost capit
termin growth rate base estim ebitda price target impli ev/sal multipl
in-lin peer current year multipl
risk includ competit slowdown revenu due macroeconom pressur clinic trial fda risk
stock price compani mention report
